Hexamethylmelamine as a single second-line agent in ovarian cancer

Alberto Manetta, Colin Macneill, Judith A. Lyter, Barbara Scheffler, Edward S. Podczaski, James E. Larson, Philip Schein

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Fifty-two patients with advanced ovarian cancer were treated with single-agent hexamethylmelamine (HMM), 260 mg/m2 po per day for 14 days followed by 14 days off drug. All patients had been previously treated with chemotherapy. Of these patients, 92% ( 48 52) received cisplatin and cyclophosphamide ± doxorubicin prior to hexamethylmelamine. Two additional patients received other cisplatin-based regimens. Fifteen percent ( 8 52) were found to have no evidence of disease (NED) at the completion of treatment with HMM. Five of these patients are alive at 12 to 65 months (median follow-up of 32 months); one patient died at 41 months of an intercurrent illness with no clinical evidence of recurrence; two patients died of recurrent tumor at 21 and 31 months. The median survival of the series of 52 patients is 11 months: 9 months for patients who did not respond versus 41 months for patients with NED post-HMM (P < 0.05). The regimen was well tolerated: moderate gastrointestinal toxicity was reported by 8 patients; only one patient reported severe gastrointestinal toxicity. Moderate neurologic toxicity (primarily sensory) was reported by 5 patients, 3 patients experienced white counts less than 2000 or platelet counts less than 100,000, and no patient sustained severe hematologic toxicity. This moderate-dose intermittent regimen was associated with moderate toxicity and was well accepted by patients. The overall response is comparable to or higher than that reported for more toxic chemotherapy regimes. Based on these data and those recently reported by other authors, hexamethylmelamine should be considered in the treatment of recurrent ovarian cancer.

Original languageEnglish (US)
Pages (from-to)93-96
Number of pages4
JournalGynecologic Oncology
Volume36
Issue number1
DOIs
StatePublished - Jan 1 1990

Fingerprint

Altretamine
Ovarian Neoplasms
Cisplatin
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynecology

Cite this

Manetta, A., Macneill, C., Lyter, J. A., Scheffler, B., Podczaski, E. S., Larson, J. E., & Schein, P. (1990). Hexamethylmelamine as a single second-line agent in ovarian cancer. Gynecologic Oncology, 36(1), 93-96. https://doi.org/10.1016/0090-8258(90)90115-2
Manetta, Alberto ; Macneill, Colin ; Lyter, Judith A. ; Scheffler, Barbara ; Podczaski, Edward S. ; Larson, James E. ; Schein, Philip. / Hexamethylmelamine as a single second-line agent in ovarian cancer. In: Gynecologic Oncology. 1990 ; Vol. 36, No. 1. pp. 93-96.
@article{ea896b38fa6b490e83e1de3ebf5d58d2,
title = "Hexamethylmelamine as a single second-line agent in ovarian cancer",
abstract = "Fifty-two patients with advanced ovarian cancer were treated with single-agent hexamethylmelamine (HMM), 260 mg/m2 po per day for 14 days followed by 14 days off drug. All patients had been previously treated with chemotherapy. Of these patients, 92{\%} ( 48 52) received cisplatin and cyclophosphamide ± doxorubicin prior to hexamethylmelamine. Two additional patients received other cisplatin-based regimens. Fifteen percent ( 8 52) were found to have no evidence of disease (NED) at the completion of treatment with HMM. Five of these patients are alive at 12 to 65 months (median follow-up of 32 months); one patient died at 41 months of an intercurrent illness with no clinical evidence of recurrence; two patients died of recurrent tumor at 21 and 31 months. The median survival of the series of 52 patients is 11 months: 9 months for patients who did not respond versus 41 months for patients with NED post-HMM (P < 0.05). The regimen was well tolerated: moderate gastrointestinal toxicity was reported by 8 patients; only one patient reported severe gastrointestinal toxicity. Moderate neurologic toxicity (primarily sensory) was reported by 5 patients, 3 patients experienced white counts less than 2000 or platelet counts less than 100,000, and no patient sustained severe hematologic toxicity. This moderate-dose intermittent regimen was associated with moderate toxicity and was well accepted by patients. The overall response is comparable to or higher than that reported for more toxic chemotherapy regimes. Based on these data and those recently reported by other authors, hexamethylmelamine should be considered in the treatment of recurrent ovarian cancer.",
author = "Alberto Manetta and Colin Macneill and Lyter, {Judith A.} and Barbara Scheffler and Podczaski, {Edward S.} and Larson, {James E.} and Philip Schein",
year = "1990",
month = "1",
day = "1",
doi = "10.1016/0090-8258(90)90115-2",
language = "English (US)",
volume = "36",
pages = "93--96",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

Manetta, A, Macneill, C, Lyter, JA, Scheffler, B, Podczaski, ES, Larson, JE & Schein, P 1990, 'Hexamethylmelamine as a single second-line agent in ovarian cancer', Gynecologic Oncology, vol. 36, no. 1, pp. 93-96. https://doi.org/10.1016/0090-8258(90)90115-2

Hexamethylmelamine as a single second-line agent in ovarian cancer. / Manetta, Alberto; Macneill, Colin; Lyter, Judith A.; Scheffler, Barbara; Podczaski, Edward S.; Larson, James E.; Schein, Philip.

In: Gynecologic Oncology, Vol. 36, No. 1, 01.01.1990, p. 93-96.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hexamethylmelamine as a single second-line agent in ovarian cancer

AU - Manetta, Alberto

AU - Macneill, Colin

AU - Lyter, Judith A.

AU - Scheffler, Barbara

AU - Podczaski, Edward S.

AU - Larson, James E.

AU - Schein, Philip

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Fifty-two patients with advanced ovarian cancer were treated with single-agent hexamethylmelamine (HMM), 260 mg/m2 po per day for 14 days followed by 14 days off drug. All patients had been previously treated with chemotherapy. Of these patients, 92% ( 48 52) received cisplatin and cyclophosphamide ± doxorubicin prior to hexamethylmelamine. Two additional patients received other cisplatin-based regimens. Fifteen percent ( 8 52) were found to have no evidence of disease (NED) at the completion of treatment with HMM. Five of these patients are alive at 12 to 65 months (median follow-up of 32 months); one patient died at 41 months of an intercurrent illness with no clinical evidence of recurrence; two patients died of recurrent tumor at 21 and 31 months. The median survival of the series of 52 patients is 11 months: 9 months for patients who did not respond versus 41 months for patients with NED post-HMM (P < 0.05). The regimen was well tolerated: moderate gastrointestinal toxicity was reported by 8 patients; only one patient reported severe gastrointestinal toxicity. Moderate neurologic toxicity (primarily sensory) was reported by 5 patients, 3 patients experienced white counts less than 2000 or platelet counts less than 100,000, and no patient sustained severe hematologic toxicity. This moderate-dose intermittent regimen was associated with moderate toxicity and was well accepted by patients. The overall response is comparable to or higher than that reported for more toxic chemotherapy regimes. Based on these data and those recently reported by other authors, hexamethylmelamine should be considered in the treatment of recurrent ovarian cancer.

AB - Fifty-two patients with advanced ovarian cancer were treated with single-agent hexamethylmelamine (HMM), 260 mg/m2 po per day for 14 days followed by 14 days off drug. All patients had been previously treated with chemotherapy. Of these patients, 92% ( 48 52) received cisplatin and cyclophosphamide ± doxorubicin prior to hexamethylmelamine. Two additional patients received other cisplatin-based regimens. Fifteen percent ( 8 52) were found to have no evidence of disease (NED) at the completion of treatment with HMM. Five of these patients are alive at 12 to 65 months (median follow-up of 32 months); one patient died at 41 months of an intercurrent illness with no clinical evidence of recurrence; two patients died of recurrent tumor at 21 and 31 months. The median survival of the series of 52 patients is 11 months: 9 months for patients who did not respond versus 41 months for patients with NED post-HMM (P < 0.05). The regimen was well tolerated: moderate gastrointestinal toxicity was reported by 8 patients; only one patient reported severe gastrointestinal toxicity. Moderate neurologic toxicity (primarily sensory) was reported by 5 patients, 3 patients experienced white counts less than 2000 or platelet counts less than 100,000, and no patient sustained severe hematologic toxicity. This moderate-dose intermittent regimen was associated with moderate toxicity and was well accepted by patients. The overall response is comparable to or higher than that reported for more toxic chemotherapy regimes. Based on these data and those recently reported by other authors, hexamethylmelamine should be considered in the treatment of recurrent ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0025174998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025174998&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(90)90115-2

DO - 10.1016/0090-8258(90)90115-2

M3 - Article

VL - 36

SP - 93

EP - 96

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -